Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,860 Mln
P/E Ratio
17.9
P/B Ratio
3.93
Industry P/E
--
Debt to Equity
0
ROE
0.29 %
ROCE
29.22 %
Div. Yield
0 %
Book Value
5.76
EPS
1.3
CFO
$311.30 Mln
EBITDA
$241.97 Mln
Net Profit
$194.60 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
| 12.36 | -8.90 | 3.99 | 55.09 | 42.82 | 36.11 | 20.31 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
| 23.93 | -9.62 | 174.74 | 102.69 | -10.93 | 95.31 | -50.70 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 6,904.81 | -- | 38.11 | |
| 71.71 | 7,308.19 | 52.48 | 23.56 | |
| 59.16 | 11,448.88 | 394.4 | 0.76 | |
| 8.13 | 9,322.72 | -- | -3.24 |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with... lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Read more
Co-Founder & Chairman
Mr. Patrick J. McEnany
Co-Founder & Chairman
Mr. Patrick J. McEnany
Headquarters
Coral Gables, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Catalyst Pharmaceuticals Inc (CPRX) stood at $ 851 Mln as on 31-Dec-24
The share price of Catalyst Pharmaceuticals Inc (CPRX) is $23.45 (NASDAQ) as of 25-Apr-2025 16:03 EDT. Catalyst Pharmaceuticals Inc (CPRX) has given a return of 42.82% in the last 3 years.
Catalyst Pharmaceuticals Inc (CPRX) has a market capitalisation of $ 2,860 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Catalyst Pharmaceuticals Inc (CPRX) is 17.90 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Catalyst Pharmaceuticals Inc (CPRX) and enter the required number of quantities and click on buy to purchase the shares of Catalyst Pharmaceuticals Inc (CPRX).
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
The CEO & director of Mr. Patrick J. McEnany. is Catalyst Pharmaceuticals Inc (CPRX), and CFO & Sr. VP is Mr. Patrick J. McEnany.
There is no promoter pledging in Catalyst Pharmaceuticals Inc (CPRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Catalyst Pharmaceuticals Inc. (CPRX) | Ratios |
|---|---|
|
Return on equity(%)
|
29.38
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
33.33
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Catalyst Pharmaceuticals Inc (CPRX) was $0 Mln.
$0.26
(
